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Recombinant human factor H (hFH) has potential for treating diseases linked to aberrant
complement regulation including C3 glomerulopathy (C3G) and dry age-related macular
degeneration. Murine FH (mFH), produced in the same host, is useful for pre-clinical
investigations in mouse models of disease. An abundance of FH in plasma suggests high
doses, and hence microbial production, will be needed. Previously, Pichia pastoris
produced useful but modest quantities of hFH. Herein, a similar strategy yielded
miniscule quantities of mFH. Since FH has 40 disulfide bonds, we created a P. pastoris
strain containing a methanol-inducible codon-modified gene for protein-disulfide
isomerase (PDI) and transformed this with codon-modified DNA encoding mFH under
the same promoter. What had been barely detectable yields of mFH became multiple 10s
of mg/L. Our PDI-overexpressing strain also boosted hFH overproduction, by about
tenfold. These enhancements exceeded PDI-related production gains reported for other
proteins, all of which contain fewer disulfide-stabilized domains. We optimized
fermentation conditions, purified recombinant mFH, enzymatically trimmed down its
(non-human) N-glycans, characterised its functions in vitro and administered it to mice.
In FH-knockout mice, our de-glycosylated recombinant mFH had a shorter half-life and
induced more anti-mFH antibodies than mouse serum-derived, natively glycosylated,org May 2021 | Volume 12 | Article 6810981
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Frontiers in Immunology | www.frontmFH. Even sequential daily injections of recombinant mFH failed to restore wild-type levels of
FH and C3 in mouse plasma beyond 24 hours after the first injection. Nevertheless, mFH
functionality appeared to persist in the glomerular basement membrane because C3-fragment
deposition here, a hallmark of C3G, remained significantly reduced throughout and beyond
the ten-day dosing regimen.Keywords: complement system, factor H, C3 glomerulonephritis mouse model, therapeutic protein, C3
glomerulonephritis, chaperonin, Pichia pastoris, protein disulfide isomerase (PDI)INTRODUCTION
Inheriting a deficiency in the ability to regulate the alternative
pathway (AP) of complement (1, 2) predisposes to disease (3).
Atypical haemolytic uraemic syndrome (aHUS) (4) and C3
glomerulopathy (C3G) (5) are kidney disorders in which
symptoms arise from excessive AP activation (6). Age-related
macular degeneration (AMD), a cause of blindness (7), is also
linked to aberrant complement regulation (8, 9) although the
mechanism is not fully established (10). In these and other
complement-related diseases, such as paroxysmal nocturnal
haemoglobinuria, treatments to suppress complement are in
clinical use, with more in the pipeline (11, 12).
Eculizumab, a mAb to complement protein C5 (13) is
approved for treating PNH (14) and aHUS (15), but showed
less promise in AMD (16) and C3G (17). Anti-VEGF drugs are
approved for wet AMD but dry AMD, likely to cause central-
vision loss in 5-10 million individuals by 2040 (18), is harder to
treat. Marginal success was reported for a PEGylated
complement C3-inhibitor peptide (19), while an anti-
complement factor D mAb did not meet clinical phase-II
milestones (20). Other antibodies and engineered-protein
therapeutics are in development (21), but there is no treatment
for dry AMD, nor for C3G. An alternative is to replace deficient
or defective genes or proteins. Precedence for protein
replacement is provided by plasma infusions to treat
complement dysregulation-linked aHUS (22–25), but regular
whole-plasma infusions may fail long term (26).
Candidates for individual protein-replacement therapy
include factor I (FI) (27, 28) and its co-factor factor H (FH)
(29, 30). Circulating in plasma, FI and FH regulate production of
the protein C3b. In the AP (1), C3 cleavage continuously
generates C3b and the anaphylatoxin C3a. Nascent C3b
remains in solution or binds covalently to nearby surfaces.
Proenzyme factor B (FB) can bind to C3b whereupon FB is
cleaved by factor D (FD) to form C3bBb. C3bBb converts more
C3 molecules to C3b. Numbers of both fluid-phase and opsonic,
surface-bound, C3b molecules thus grow rapidly (31) unless this
is halted by regulators. Self (host) cells, unlike most bacteria,
display their own membrane-bound regulators of C3b
amplification. This implies FI and FH (32) are needed to
suppress C3b amplification in fluid phase and on non-
membrane enclosed structures, including extracellular matrix,
that are recognised as “self” by FH. On self surfaces, FH
accelerates decay of surface-bound C3bBb and is a cofactor for
C3b proteolysis by FI to iC3b. iC3b, also an opsonin, can beiersin.org 2cleaved to yield soluble C3c and C3dg, which is further degraded
to C3d and resides long-term on the surface (3). Mutations and
SNPs in the FH gene (CFH) pre dispose to disease (33, 34). Some
are highly penetrant (35, 36). Crucially, FH has other functions
(37) than suppressing complement, and the loss of one or more
of such “non-canonical” roles may contribute to dry AMD (38).
Administering fully functional full-length FH to patients with
disease-causing loss-of-function CFH mutations has the
advantage that it makes no assumptions about which function
of FH is lost or which molecular mechanism underlies disease.
CFH-deficient mice, an animal model of C3G (39), allow
exploration of FH-replacement therapy. Unregulated C3b
amplification in CFH-/- mice depletes plasma C3, as seen in
some C3G patients. In humans with C3G, C3 fragments are
covalently deposited (40) on surfaces such as the glomerular
basement membrane (GBM). Similar linear electron-dense
deposits are observed along the GBM of CFH-/- mice.
Deficiency of both FH and Crry, a mouse-specific
transmembrane complement regulator, yielded milder renal
injury (41). Homozygosity for mouse (m)FH mutant W1206R
(i.e., disease-related W1183R in human (h)FH) that lacks
surface-recognition functionality, causes a more acute and
aHUS-like phenotype than total FH deficiency (42). Fed a
high-fat diet, aged CFH+/- mice develop ocular symptoms
reminiscent of AMD (43). In trials of FH-replacement therapy
in CFH-/- mice, serum-derived hFH restored C3 levels and
attenuated glomerular iC3b deposits, but formation of anti-
hFH antibodies precluded long-term studies (29). Similar
outcomes were achieved in CFH-/- mice crossed with
transgenic mice expressing human CFH (44). Studies using FH
purified from murine plasma further supported the case for
therapeutic intervention with FH (45). Given the abundance of
FH in plasma (200-300 mg/L), multiple-tens of mg are required
for a robust animal trial of systemic administration while
kilograms of therapeutic-grade recombinant FH would be
needed for clinical trials. Were intravitreal injection of small
doses of recombinant FH to prove effective for AMD treatment,
large quantities of affordable material would still, eventually, be
needed for a global rollout.
Hence an obstacle to FH therapy is access to sufficient protein.
FH (32) is a soluble 155-kDa single-chain glycoprotein. Like
other regulators of complement activation (RCA) family
members (46), it contains a chain of complement-control
protein modules (CCPs) (aka short consensus repeats); 20 in
the case of FH (47). Attempts to produce hFH using mammalian
(Cos7) (48) and insect cells (49) yielded sub-mg quantities. Up toMay 2021 | Volume 12 | Article 681098
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type N-glycans) was achieved using the moss Physcomitrella
patens (50, 51), allowing an encouraging small, short-timescale,
trial in CFH-/- mice (51). Scaling this up for clinical trials would
be very challenging. Recombinant production of 10-mg
quantities of FH was, eventually, achieved (52) in Pichia
pastoris (53). After harvest of secreted FH its P. pastoris-
specific high-mannose N-glycans were trimmed to single
GlcNAc residues. As expected (54), trimmed hFH retained
biological functionality in vitro (52). Yields of hFH from a
synthetic gene far exceeded the undetectable levels obtained
from a native-sequence gene (52), but were 50-fold lower than
those of smaller FH segments produced in P. pastoris (55), and
orders of magnitude lower than those of many other proteins
made in this host (56).
Herein, we aimed to produce sufficient mFH for extensive
trials in mouse models. Use of the P. pastoris-based strategy that
had proved moderately successful for hFH failed, with yields
lower even than those reported for moss (50, 51). To make FH,
all of its 20 domains, each containing two disulfides, must fold
correctly. We hypothesized that limited levels of protein disulfide
isomerase (PDI) activity within the endoplasmic reticulum (ER)
might retard production. To test this, we applied a PDI-co-
expression-in-P. pastoris strategy to mFH and hFH production.
This afforded production gains exceeding those reported for
other categories of (generally smaller) proteins. The mFH
produced was active in vitro as well as in vivo albeit with a
short serum half-life. Despite this, mFH treatment reduced C3
deposits in the GBM of treated animals.MATERIALS AND METHODS
Synthetic Genes
An expression-optimised synthetic gene for mFH was procured
from GeneArt Life Technologies (now ThermoFisher). A
different version was procured from DNA 2.0 (now ATUM)
(Supplementary Figure 1A). The GeneArt-designed DNA,
supplied in pPIC3.5K, was re-cloned into pPICZaB. The DNA
2.0 gene was supplied in a proprietary P. pastoris vector
(pJexpress 912) which (like pPICZaB) utilises zeocin selection
and uses the yeast a-factor signal sequence to promote secretion
of the recombinant protein. An expression-optimised gene
(Supplementary Figure 1B) for P. pastoris protein disulfide
isomerase (PDI) was purchased in pPIC3.5K from GeneArt
Life Technologies. Maxi-preps were performed in E. coli, then
the plasmid was linearized for integration at the AOX1 locus with
Sac1, phenol-chloroform extracted, and ethanol precipitated.
Transformations
For FH production, plasmids were transformed into
electrocompetent P. pastoris KM71H cells (MutS) (Invitrogen). The
pPICZaB plasmid containing GeneArt DNA for mFH was
additionally transformed into X33 (Mut+) and SMD1168H (Mut+,
Protease A deficient) strains. For PDI, KM71 P. pastoris cells (His4-)
were transformed with the synthetic gene for P. pastoris PDI inFrontiers in Immunology | www.frontiersin.org 3pPIC3.5K (carrying His4). For all transformations, electrocompetent
cells were added to linearised DNA and transferred to an
electroporation cuvette for pulsing (on ice) using a Biorad
Genepulser II. Immediately afterwards, ice-cold 1 M sorbitol or
yeast-peptone-dextrose-sorbitol (YPDS; YPD with 1 M sorbitol)
medium was added and the cuvette incubated (30°C) for three
hours. For FH-producing strains, aliquots were spread on YPDS
plates containing 100 µg/mL to 500 µg/mL zeocin, and incubated
(30°C) until colonies grew. These were re-streaked onto fresh YPDS
agar plates (containing same zeocin concentration as the original
plate) and incubated for three further days (30°C). PDI-strains, after
transformation, were plated onto minimal-dextrose plates that were
incubated (30°C), then single colonies were re-streaked on minimal-
dextrose plates and incubated for three further day (30°C).
Small-Scale FH-Production Tests
Multiple small-scale cultures were grown from single colonies in
buffered glycerol-complex medium (BMGY i.e., 1% yeast extract,
2% peptone, 1% (v/v) glycerol, 400 mg/L biotin, and 0.1 M
potassium phosphate, pH 6.0), before cells were transferred to
25 mL of buffered methanol-complex medium (BMMY i.e. 1%
yeast extract, 2% peptone, 1% (v/v) methanol, 400 mg/L biotin,
and 0.1 M potassium phosphate, pH 6.0). Baffled flasks
containing cells suspended in BMMY were incubated at 20°C
in a shaking incubator for four days with daily methanol feeds.
On day 4, cells were spun out and discarded. The supernatant
was filtered before addition of phenylmethylsulfonyl fluoride
(PMSF) and ethylenediaminetetraacetic acid (EDTA), (to 0.5
mM and 5 mM, respectively). Protein expression was checked
using sodium dodecylsulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) with Coomassie Blue staining or western blotting.
Treatment of samples prior to SDS-PAGE with Endo Hf, to
remove P. pastoris-derived high-mannose N-glycans, was
achieved by adding to a 50 µL aliquot of supernatant, 1 µL of a
1:3 dilution of stock enzyme (NEB, 1,000,000 units/ml) and
incubating for one hour at 37°C.
Small-Scale PDI-Production Tests
Small-scale test growths, from single colonies of PDI-
transformed cells growing on minimal-dextrose plates, were
performed as above. Both supernatants and cell pellets were
retained, post-harvest, for SDS-PAGE. To obtain protein from
pellets, they were vortexed with NuPAGE sample buffer
containing 2% lithium dodecyl sulfate and incubated (100°C)
for 120 s then re-vortexed and centrifuged. Based on the
appearance of appropriate bands, a colony judged to be
producing PDI (i.e., KM71-PDI) was selected, and transformed
with FH-encoding DNA, as above. Subsequent small-scale FH
production tests were also performed as above.
Fermentations
The best 10-L fermentation for FH production, prior to co-
expression with PDI, was performed in a Bioflo 3000 (New
Brunswick Scientific). A single colony picked after re-streaking
on a 500 µg/mL-zeocin YPD plate was used to inoculate a 10-mL
BMGY (500 µg/mL zeocin) seed culture that, after incubation
(30°C, three days), was used to inoculate two BMGY (500 µg/mLMay 2021 | Volume 12 | Article 681098
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days at 30°C, the starter culture was inoculated into 7.5 L of
fermentation basal salts medium (2.5% (v/v) glycerol, 0.425%
potassium hydroxide, 1.5% magnesium sulphate heptahydrate,
1.82% potassium sulphate, 0.095% calcium sulphate, 2.3% (v/v)
ortho-phosphoric acid, 0.025% (v/v) antifoam 206 (Sigma–
Aldrich) and 0.4% (v/v) high-purity grade fermentation trace
mineral salts (PTM1 salt, Amresco). The pH was adjusted (after
inoculation) to 5.0 using 34% (v/v) ammonia solution. Cell mass
was grown in a batch-mode glycerol-fed phase at 30°C (1.2 mL of
PTM1 salts added for every 100 mL glycerol) to reach a wet-cell
mass of 200 g/L prior to induction with 0.5% (v/v) methanol
(15°C). Following induction, methanol was fed in batches so as to
maintain a level of 1.5% (v/v) (1.2 ml PTM1 salts added for every
100 mL of methanol; 1% sorbitol (w/v) and 0.3% tryptone
included in each methanol feed).
Fermentations of the CFH/PDI-co-expressing strain were
performed in a similar manner except a continuous feeding
process was used during induction. In this phase, a pump was set
to feed methanol/glycerol (in a 4:1 mixture, contained 10 mM
PMSF) at an initial 50 mL/hour, which increased daily to 88 mL/
hour over a four-day induction period. Additions to achieve a
final concentration of 0.3% tryptone were made approximately
every four hours.
Purification of Recombinant Murine FH
After spinning out cells, supernatant was diluted, and pH
adjusted to 6.0. Factor H was captured on Toyopearl SP-650
resin (Tosoh Biosciences) (eluted with 50-500 mM NaCl
gradient). After incubation with Endo Hf (New England
BioLabs), released sugars and non-deglycosylated material were
removed by passage through concanavalin A resin, then samples
were dialysed into glycine buffer, pH 9.5 (90 mM NaCl). This
material was loaded onto a column containing MonoQ or
SourceQ (Sigma) and eluted with a gradient to 1 M NaCl.
After dialysis into PBS, pH 7.4, FH was further purified by
size-exclusion chromatography on Superdex 200 (Sigma). In an
attempt to enrich non-“clipped” intact protein, a small aliquot
from the peak fraction eluted from the size-exclusion column
was loaded onto a ceramic hydroxyapatite column in 10 mM
sodium phosphate, 200 mM NaCl, pH 6.5, and eluted with a
gradient to 500 mM sodium phosphate, 200 mM NaCl, pH 6.5.
This sample was used for co-factor assays.
Surface Plasmon Resonance
Measurements
All surface-plasmon resonance (SPR) experiments were performed
on a BIAcore T200 instrument (GE Healthcare) at 25°C using
HBSP+ (10 mM HEPES, 150 mM NaCl and 0.05% w/v surfactant
P20, GEHealthcare) withoutMgCl2 unless stated. Human C3b, C3d,
FD and FB were purchased from CompTech, Inc. Mouse C3b,
prepared from serum-derived C3, and mouse FB also purified from
serum using standard procedures, were gifts from Professor Santiago
Rodriguez de Cordoba (Centro de Investigaciones Biologicas,
Madrid). Murine C3d was recombinant in origin, and was a gift
from Dr Jonathan Hannan (University of Colorado).Frontiers in Immunology | www.frontiersin.org 4We measured in various combinations the affinities of
recombinant mFH, serum-purified native mFH and hFH, for
immobilized mouse and human C3b and C3d. A two-fold
dilution series of FH solutions (from 2 µM to 6 nM) was
injected (twice, i.e., two replicates) over the chip at 50 µl/min for
180 s, followed by a dissociation-observe time of 300 s. The chip
surface was regenerated between injections with a double injection
of 1 M NaCl (50 µl/min for 30 s). Equilibrium data were analysed
using the Biacore evaluation software and a 1:1 binding model.
We used SPR to measure the ability of FH to accelerate decay
of a C3 convertase (C3bBb). A CM5 chip (GE Healthcare) was
used with a running buffer of HBSP+ containing 1 mMMgCl2. A
total of 1500 RU of murine C3b was amine coupled to each of
flow-channels 2 and 4 (flow-channels 1 and 3 were left C3b-free
and used for reference). To assemble C3 convertase in each flow-
channel, a mixture of (either human or murine) 500 nM factor B
and 50 nM human factor D was flowed (10 µl/minute) over the
chip for 180 s. An initial dissociation phase (240 s) allowed
observation of some intrinsic convertase decay (Bb loss) prior to
injection with either 40 nM or 100 nM (used to measure decay of
human C3 convertase bymouse FH) solutions of FH (10 µl/min for
180 s). After a further dissociation phase of 240 s, the surface was
regenerated with a 30-second injection (10 µl/min) of 1 M NaCl.
Co-Factor Assay
A standard fluid-phase co-factor assay was used to estimate in
vitro co-factor activity of mFH for human FI-mediated cleavage
of human C3b. In brief, each reaction was performed in a final
volume of 20 µl that included 850 nM C3b and either 110 nM or
220 nM FI. The reaction (37°C for two hours) was started with
the addition of either 300 nM or 600 nM FH (or 0 nM FH in the
negative control). It was terminated by addition of NuPAGE
lithium dodecyl sulfate sample buffer and NuPAGE reducing
agent, and then heated at 100°C for 120 s. The presence of
products (i.e. cleaved a’-chain) was detected by the appearance
of bands in SDS-PAGE.
In Vivo Studies With Recombinant FH
CFH-/- mice were generated as previously described (39) and
backcrossed onto the C57BL/6 genetic background. Mice used
were 7-9 weeks old. All experimental procedures were conducted
in accordance with institutional guidelines. Blood was collected
into tubes containing 10 mM potassium EDTA in distilled water,
via tail venesection, before injection and at indicated time points
thereafter. Plasma was separated by refrigerated centrifugation
(2000 g for 600 s) prior to storage at -80°C. Mice were culled at
indicated time points, and kidneys collected into PBS and snap
frozen in optimal cutting temperature (OCT) embedding matrix
(CellPath) for storage at -80°C. All proteins administered to the
animals were subjected to lipopolysaccharide (LPS) removal
(57) and were confirmed to be LPS-free by the method of
Moesby et al. (58). Protein solutions (0.5 mL in PBS vehicle)
were administered by intraperitoneal (IP) injection.
For experiment 1, four mice were injected with 0.5 mg
recombinant mFH, four mice received 1.0 mg recombinant
mFH, two mice received serum-derived mFH and two mice
received vehicle only (PBS). Mice were bled pre-injection, and atMay 2021 | Volume 12 | Article 681098
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experiment 2, five mice were injected daily with 0.5 mg
recombinant mFH, two mice were injected daily with 0.4 mg
recombinant hFH (dictated by availability of protein at that time)
and five mice were injected daily with vehicle only. Daily
injections were administered for ten days in total. Mice were
bled pre-injection, and at 24 hours, five days and 11 days (i.e., 24
hours after final injection). Mice were culled at 11 days post-
initial injection.
For the experiment to assess the immunogenicity of FH, mice
(eight weeks old, wild-type and CFH-/-) received 20 µg of protein
in sterile saline via ip injection on Day 0 and on Day 28. Animals
were bled via tail vein venesection into 10 mM EDTA in PBS
every seven days until day 41 when they were terminally
exsanguinated under anaesthesia, in accordance with animal
license P35D9C60C granted by the UK Home Office.
Measurement of C3 and FH
Levels of FH in mouse plasma were measured by capture with a
sheep anti-hFH cross-reacting antibody (1:1000) (ABIN 113017)
followed by detection with a cross-reacting goat anti-hFH
biotinylated antibody (5 mg/ml stock) (Quidel A312) and a
streptavidin alkaline phosphatase (1:2000) (BD Pharmingen
554065) reporter. Results were quantified by reference to a
standard curve of recombinant murine FH protein. Levels of
human FH in mouse plasma were measured by capture with an
anti-FH monoclonal antibody (2 µg/ml) (Ox24, Thermo
MA170057) and detection with a polyclonal sheep anti-human
FH antibody (1mg/ml) (AbcamAB8842) and a donkey anti-sheep
antibody (40 µg/ml) (peroxidase-conjugated) (Jackson Lab: 713-
035-147) and tetramethylbenzidine. Results were quantified by
reference to a standard curve of recombinant human FH protein.
To quantify production of recombinant hFH with and without
PDI, an ELISA, referenced to a standard curve of human FH
supplied by Complement Technologies, was used. For this assay,
the N-terminal domain of PspC (prepared according to (59) was
used to capture FH, and then biotinylated Ox 24 (Lifespan
Biosciences), streptavidin peroxidase polymer, ultrasensitive
(Sigma) and tetramethylbenzidine were used for detection. C3
levels were measured by ELISA using goat anti-mouse C3
antibody (0.5 µg/ml) (MP Biomedicals 55463) as previously
described (60). Results were quantified by reference to a
standard curve generated from acute-phase sera containing a
known quantity of C3 (Calbiochem).
Detection of Murine Anti-FH Antibodies in
Mouse Plasma
Two ELISA protocols were used to detect anti-FH antibodies. (i)
In experiments aimed at restoring complement regulation with
various regimens of FH administration, MaxiSorp ELISA plates
were coated with 0.0625 µg of recombinant mFH or hFH that
had been diluted in 50 mM sodium carbonate, pH 9.6. After
washing and blocking with 1% BSA in PBS, the plasma samples
to be tested were added at a dilution of 1:50 and incubated at
room temperature (one hour). After washing, plates were
incubated for a further hour at room temperature with a goatFrontiers in Immunology | www.frontiersin.org 5anti-murine IgG Ab labelled with alkaline phosphatase (Sigma
A3438). After additional washing, enzymatic activity was
revealed using SIGMA-FAST p-nitrophenylphosphate tablets.
Antibody titres were expressed as arbitrary ELISA units
calculated as optical density (405 nm) of the sample multiplied
by 50. (ii) In experiments designed to test immunogenicity of FH,
Nunc maxiSorp ELISA plates were coated with 5 µg/ml (50 µl per
well) of native or recombinant mFH diluted in PBS. After
washing and blocking with 0.1% Tween in PBS, plasma to be
tested was added at a dilution of 1:100 in triplicate wells and
incubated (one hour, room temperature). After washing, plates
were incubated for a further hour (room temperature) with sheep
anti-murine IgG antibody labelled with horseradish peroxidase
(anti-sera was used at a 1/2000 dilution after reconstitution in
50% v/v glycerol according to manufacturer’s instructions, #515-
035-071 Jackson ImmunoResearch via Stratech Scientific, UK).
After additional washing, enzymatic activity was revealed by
addition of TMB solution (Universal Biologicals Ltd). The assay
was stopped using an equal volume of 10% H2S04, then A
450 nm
measured. Means of triplicate readings are shown. For a positive
control, a mouse anti-FH mAb (2a5, 5 mg/ml stock, a gift from
Professor Claire Harris), was diluted 1/250,000 or 1/750,000. For
a negative control, PBS was used. To compare the immune-
reactivity of mouse terminal bleed sera generated with antigens
of different origin, an ELISA protocol was performed as above,
with native or recombinant mFH coated to the plate.
For Western blot (WB)-based analysis of plasma C3, samples
were separated using a 10% (w/v) polyacrylamide gel under
reducing conditions. The detection antibody was goat anti-serum
to mouse C3 (0.8 µg/ml) (MP Biomedicals 55444) and the
secondary antibody was HRP-conjugated anti-goat IgG (5.2
µg/ml) (Sigma A9452). Blots were visualized using Pierce
electrochemiluminescence Western blotting substrate (Thermo
Scientific). For glomerular immunostaining, cryosections from
snap-frozen kidneys were fixed in acetone for 600 s. C3 was
detected with FITC-conjugated anti-mouse C3 antibody (10 µg/
ml) (MP Biomedicals 55500). C3d was detected using the biotin-
blocking system (Dako) and a biotinylated goat anti-mouse C3d
antibody (5 µg/ml) (R+D systems BAF2655) followed by Avidin-
Alexa 488 (5 µg/ml) (Invitrogen S11223). IgG was visualized with
a FITC-conjugated goat anti-mouse IgG antibody (11.5 µg/ml)
(Sigma F5387). Twenty glomeruli were visualized per section and
fluorescence intensity expressed in arbitrary units.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism
(version 8.0; GraphPad). Kruskal-Wallis with Dunn’s multiple
comparisons test was used when comparing multiple groups.RESULTS
Murine FH Cannot Be Made in Standard
P. pastoris Strains
Our initial efforts to produce mFH employed a strategy used
to make its human orthologue (52). Thus, we expressed inMay 2021 | Volume 12 | Article 681098
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From 25-mL protein-production trials we hoped for Coomassie
Blue (CB)-detectable SDS-PAGE bands verifiable by WB and,
due to the presence of 40 disulfide bonds, migrating differently
under reducing and non-reducing conditions. We tested P.
pastoris KM71H, SMD1168H and X-33 (Invitrogen/
ThermoFisher) transformed with plasmids containing either of
two codon-modified genes for mFH. To export mFH, we
explored use of mammalian and yeast secretion signals.
In the most promising trial, KM71H was transformed with a
plasmid (pJe912) containing a mFH gene synthesized by DNA2.0
(now ATUM). This utilises zeocin for selection and the yeast a-
mating factor for secretion. Secreted protein was Endo Hf-treated
to prune back high-mannose N-glycans. Production of mFH was
so low that to obtain WB-detectable gel bands (Supplementary
Figure 2A) we first had to enrich mFH on heparin-affinity resin.
We subsequently grew this strain in a fermentor, varying zeocin
concentrations and exploring growth media, feeding protocols
and protease inhibitors. Most successful was a fermentation in
basal-salts medium with sorbitol and tryptone added at each
methanol feed over three days of post-induction culture. After cell
removal, harvested supernatant was loaded on SP-sepharose. Salt
elution and Endo Hf treatment yielded CB-detectable SDS-PAGE
FH bands (Supplementary Figures 2B, C). Under reducing
conditions only, additional protein bands appeared beneath the
main band. N-terminal sequencing confirmed clipping between
Arg906 and Asp907, in an eight-residue insertion with respect to
hFH within CCP 15, generating two disulfide-linked
polypeptides. Passage over lectin-affinity resin removed non-
deglycosylated material but this, followed by anion-exchange
and size-exclusion chromatography, failed to resolve clipped
from non-clipped mFH. Some enrichment of non-clipped
material was subsequently obtained by passage over ceramic
hydroxyapatite (not shown) but it was not sufficient to justify
the accompanying loss of yield.
Despite trying to optimize fermentation, yields of <1 mg/L
purified mFH, were <5% of those for hFH. Efforts to reduce
proteolysis, including use of protease-deficient P. pastoris strain
SMD1168H, did not boost production or reduce clipping. Attempts
to enhance gene-copy number by selecting for resistance to higher
zeocin levels failed. The 40 disulfides within FH might overwhelm
disulfide-forming and protein-folding machinery within P. pastoris
ER. Thus, we explored co-expression of the synthetic mFH gene
with an extraneous gene for P. pastoris PDI.
Co-Expression With PDI Increases
Yield > 100-Fold
To make a PDI-overproducing strain, codon-modified DNA
encoding P. pastoris PDI was inserted into pPIC3.5K
(ThermoFisher) under the AOX1 promoter and transformed into
KM71 cells to create P. pastoris KM71-PDI. KM71 cells have aHis4
mutation that is complemented by pPIC3.5K. KM71-PDI cells were
transformed with pJe912 containing codon-modified mFH DNA,
and colonies of KM71-PDI-FH selected with zeocin. Small-scale
trials of the PDI andmFH co-expressing cells made sufficient mFH
for WB identification without pre-enrichment, a major increase in
yield over non-PDI strains (Supplementary Figure 2D). UsingFrontiers in Immunology | www.frontiersin.org 6qPCR (Supplementary Figure 3A,B) we found two copies of the
FH gene and two copies of the PDI gene were responsible for these
good yields. Moreover, qRT-PCR (Supplementary Figure 3B)
suggested that post-induction, levels of RNA transcripts for mFH
and PDI were 100-fold and 200-fold higher, respectively, than those
for the housekeeping (61) b-actin gene Act1.
Aiming to make more mFH, exploratory ten-litre
fermentations of KM71-PDI-CFH were performed. The best
involved daily pumped feeds, for four days post-induction,
with 4:1 glycerol:methanol plus tryptone, and daily addition of
Pefabloc SC. Sampling by SDS-PAGE of the medium during
induction, without concentration or enrichment, produced CB-
stained candidate-mFH bands (Figure 1A). After centrifugation,
mFH was captured from diluted supernatant by cation-exchange
chromatography (Toyopearl SP-650). Eluted fractions contained
predominantly mFH (Supplementary Figures 2E, F) but this co-
purified with “clipped” mFH as before. The peak 5-mL fraction
contained 4.5 mg/mL protein and pooled fractions contained 420
mg in total. These were Endo Hf-treated, run over a lectin-affinity
column, then divided into three for anion-exchange
chromatography (Figures 1B, C), yielding 78 mg mFH in total.
This exceeds by >200-fold the yield from non-PDI strains.
Contamination with clipped mFH could not be resolved under
conditions compatible with structural integrity and preservation
of yield.
The yield of mFH from these P. pastoris cells was a striking
improvement compared to cells not producing extra PDI. Unlike
in the case of mFH, a codon-modified gene for hFH did express
reasonably well in P. pastoris KM71H without extra PDI. We
wondered whether co-expression with PDI might also improve
hFH production. We transformed KM71-PDI and KM71H
strains with pPicZa containing the same codon-modified FH
gene used previously (52), then performed an ELISA to compare
hFH production between the two strains. We found (Figure 2)
that co-production with PDI in P. pastoris substantially increases
hFH yields.
In Vitro Tests of mFH Function
Previous work showed hFH binds human C3b, the activated
fragment of C3, with a KD of 0.3 -1.3 µM (62–64) when C3b is
immobilised on an SPR chip. Binding to C3b is a prerequisite of
both the cofactor activity of FH and its decay-accelerating
activity (DAA) towards the C3 convertase, C3bBb (31). We
therefore measured binding of our mFH to mouse C3b amine
coupled to a C1 chip. By flowing recombinant mFH over C3b in
the SPR instrument, and fitting responses to a 1:1 equilibrium
model, we obtained a KD of 1.2 µM, similar to that of the hFH:
C3b interaction. Parallel measurements of recombinant mFH
binding to human C3b yielded KD = 1.6 µM (Figures 3A, B).
To measure DAA, we modified a published protocol (65).
Thus, we formed mouse C3bBb by flowing FD mixed with
murine FB (mFB) and murine C3 (Figure 3D) over murine
C3b “seeds” amine coupled to a CM5 SPR chip. Subsequently,
murine C3bBb irreversibly decays over several minutes. By
flowing recombinant mFH over mouse C3bBb we observed
decay acceleration. We found that native mFH, purified from
mouse serum, was slightly less active than recombinant mFH inMay 2021 | Volume 12 | Article 681098
Kerr et al. PDI-Assisted Complement Factor H Productionthis assay. Minor differences between native FH and FH were
likewise reported in DAA assays on hFH (52). In a parallel
experiment, we found that mFH did not accelerate decay of the
human C3bBb complex (Figure 3C). We found that complexes
did not form between human C3b and mFB, or mouse C3b and
human FB. We also showed that recombinant mFH had cofactor
activity for cleavage of human C3b by human FI (Supplementary
Figure 4).
In Vivo Tests of Recombinant
mFH Efficacy
Previously, IP injection of native (serum-derived) mFH or hFH
into CFH-/- mice temporarily restored serum C3 levels by
establishing fluid-phase regulation of C3 consumption (29, 45).
It also reduced C3-fragment deposition along the GBM. We
asked whether FH produced in yeast could achieve these
therapeutically desirable goals. Endo Hf-treated samples ofFrontiers in Immunology | www.frontiersin.org 7recombinant FH were depleted of lipopolysaccharides (LPS),
then dialysed into PBS and adjusted to 1-2 mg/mL protein (LPS
levels < 0.1 x 10-4 µg/mL) ready for injection. SDS-PAGE (Figure
1D) confirmed that the small proportion of proteolytically
clipped FH remained unchanged during these procedures. We
injected, IP, CFH-/- mice with 0.5 mg or 1.0 mg recombinant
mFH. We compared these “low-dose” and “high-dose” groups
with a third group; two of these received 0.5 mg native mFH
from mouse serum, and two received PBS only. Levels of FH and
C3 in plasma were monitored (Figures 4A, B).
At six hours post-injection (p.i.), plasma FH levels in CFH-/-
mice receiving mFH attained approximate parity with levels in
non-treated wild-type (WT) mice. Plasma FH levels were more
elevated for the higher than the lower dose of recombinant mFH
(Figure 4A). At 24 hours p.i., plasma mFH had approximately
halved for both doses of recombinant mFH. Conversely, plasma
FH levels in CFH-/- mice 24 hours p.i. of native mFH remainedA B
D C
FIGURE 1 | Production of recombinant mFH by fermentation of KM71-PDI-CFH. (A) Lanes 0-5, deglycosylated samples (10 µL) from fermentation days (d) 0-5:
induced with methanol, d1; fed with methanol, d2-4; harvested, d5. Lane 6, as lane 5 with PMSF added post-harvest. Lane A, MWt markers (MWM) (kDa). NR/R;
run under non-reducing/reducing conditions. (B) Purification on Source Q of one third of the material harvested and initially captured on cation-exchange resin;
elution profile (0-1 M NaCl over 12 column volumes). (C) Lane L, loading sample (10 µL); Lane M, MWM; other lanes, aliquots of 2 µL (black bar) or 10 µL (grey bars)
from main-peak fractions; Arrow, “clipped” protein fragments. In frames (A, C), candidate rmFH bands are boxed. (D) Samples of recombinant mFH used in vivo; 5
µL loaded per well. “Pre”, before LPS removal. “Post”, after LPS removal. Lane A, MWM.May 2021 | Volume 12 | Article 681098
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recombinant mFH was cleared faster than native mFH.
We measured secondary consequences of elevated plasma FH
in CFH-/- mice by monitoring C3 (Figure 4B). At six hours p.i., all
mice dosed with mFH had elevated plasma C3 levels suggestingFrontiers in Immunology | www.frontiersin.org 8restoration of control of fluid-phase activation (that otherwise
depletes plasma C3). Higher C3 levels were measured in mice that
received 1.0 mg recombinant mFH, or 0.5 mg of native mFH,
compared to those receiving 0.5 mg recombinant mFH. These
higher values resemble serum C3 levels in non-treated WT mice.A C
B D
FIGURE 3 | In vitro assays of recombinant mFH. (A) A recombinant mFH dilution series was flowed over murine C3b amine-coupled to a C1 chip [233 response
units (RU)] in the SPR instrument, and equilibrium data plotted (insert). (B) The recombinant mFH was flowed over human C3b (258 RU), as in (A) KD estimates in
(A, B) assumed reversible 1:1 binding. (C) In a decay-acceleration assay, human C3b was coupled to a CM5 chip (1140 RU) then human FB and FD were flowed
over it, forming human C3bBb. Its decay rate accelerated upon injection (arrow) of 100 nm hFH. No such increase was elicited by recombinant mFH, or FH from
mouse serum. (D) Murine C3b was amine coupled to the CM5 chip (1510 RUs), then mouse FB and FD were injected, forming mouse C3bBb. Its decay rate was
increased following injection of 40 nM mFH.FIGURE 2 | Comparison of recombinant hFH production with and without co-production of PDI. KM71H, or two colonies of KM71-PDI, were transformed with
pPicZa containing a gene for human FH. After selection with 300 or 500 µg/mL zeocin, four single colonies in each case were used to inoculate 25-mL test growths.
An ELISA (see Methods) was used to estimate recombinant hFH production in supernatants.May 2021 | Volume 12 | Article 681098
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groups of mice receiving recombinant mFH. Conversely, plasma
C3 levels did not fall at 24 hours in mice receiving native mFH.
Hence C3 concentrations correlated broadly with plasma FH
levels. We ascertained whether the C3 detected was intact
(Figure 4C). Plasma C3 sampled at six hours p.i. with 1.0 mg
recombinant mFH or 0.5 mg native mFH, retains an intact a-
chain. After 24 hours, C3 inmice treated with native mFH remains
largely intact. Conversely the lower quantities of C3 in mice
receiving recombinant mFH do not possess an intact a-chain.
Dense glomerular deposits of C3 fragments feature in C3G. We
sought these in CFH-/- mice using C3 immunostaining. Figure 5
shows representative comparisons of glomerular C3-fragment
deposition at 24 hours p.i. for recombinant mFH, native mFH or
PBS. In PBS-treated CFH-/- mice, linear staining of capillary walls
resembles C3G (29, 39, 45). Significant reductions in capillary-wall
C3 immunostaining were found in CFH-/- mice dosed with
recombinant mFH. In CFH-/- mice receiving native mFH,
capillary wall staining was also reduced (Figure 5B), and tubulo-
interstitial staining evident, as reported in healthy wild-type mice
(45). C3 staining was reduced 24 hours after recombinant mFH
injection, despite the decline of plasma FH and C3 levels.We sought
IgG staining at the GBM, indicating immune complex formation as
might be triggered by anti-FH antibodies, but none was observed.Frontiers in Immunology | www.frontiersin.org 9In sum, these studies show: (i) high plasma levels of mFH and
intact C3 persist 24 hours after dosing CFH-/- mice with native
mFH; (ii) dosing with recombinant mFH temporarily raised
plasma mFH levels but recombinant mFH was cleared faster
than native mFH; (iii) due to faster clearance, injected
recombinant mFH controlled fluid-phase C3 consumption less
effectively than did native mFH; (iv), the protective effects of
recombinant mFH, in terms of preventing C3 fragment deposition
along the GBM, persisted after serum levels of the administered
recombinant protein had fallen to 50% of WT levels.
Clearance of recombinant mFH complicates assessment of
potential benefits. We therefore studied in CFH-/- mice the
cumulative outcome of ten daily 0.5-mg IP injections of
recombinant mFH. A second group of CFH-/- mice received
PBS. In parallel, a similar dosing regimen was followed (0.4 mg
daily) using recombinant hFH. Samples were taken pre-injection
and at 24 hours, five days, and 11 days after the first injection of
the series. At 24 hours (Figures 6A, B), plasma FH levels in mice
receiving recombinant mFH or hFH were elevated, consistent
with levels observed in the previous experiment following a
single injection of recombinant mFH. Similar levels were
detected at day 5, but by day 11 FH levels reverted to pre-
injection values. At 24 hours (Figures 6C, D), levels of intact C3
in CFH-/- mice dosed with recombinant mFH or hFH, at ~80 µg/A
B
C
FIGURE 4 | Plasma complement profile in CFH-/- mice after injection of mFH. (A) Plasma FH levels, and (B) plasma C3 levels, pre-injection (P) and six hours and 24
hours after IP injection of recombinant mFH (rec. mFH), FH purified from mouse serum (plasma mFH), or vehicle (PBS). Mean wild-type (WT) plasma C3
concentration (dotted line) = 230 µg/mL. Horizontal bars denote mean values. *P=0.0034 versus pre-injection value, Dunn’s Multiple Comparisons. (C) Western blot
(reducing conditions) showing non-cleaved C3 a-chain after mFH injection.May 2021 | Volume 12 | Article 681098
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approximately double those in mice receiving PBS. Subsequently,
plasma C3 levels declined, and they did not differ significantly
from PBS-injected mice at 11 days.
We tried to detect anti-FH antibodies in CFH-/- mice plasma
after injection of recombinant FH (Figures 6E, F). No anti-FH
antibodies were detected at 24-hour and five-day time points, but
substantial levels were evident at day 11. In a previous study of
native human FH administration to CFH-/- mice, anti-FH
antibodies were also observed after ten daily doses (29). To
further investigate immunogenicity of recombinant mFH,
experiments were performed in which wild-type mice and
CFH-/- mice were injected with either recombinant mFH or
native mFH (at day 0 and again at day 28), and anti-FH
antibodies measured in blood weekly prior to terminal bleed at
41 days (Figure 7). Recombinant mFH was consistently more
immunogenic than nativemFH in both wild-type (Figure 7A) and
CFH-/- mice (Figure 7B). A response to recombinant mFH is
evident in wildtype mice which does not cross-react significantly
with native FH (Figure 7A), suggesting antigenic epitopes exist on
recombinant mFH that are distinct to the native FH in these mice.
Returning to the daily-dose experiment, Figure 8A shows
representative images of glomerular C3 immunostaining at day
11 (24 hours after tenth injection). In vehicle-only controls,
linear capillary wall staining with an anti-C3 antibody is evident
as expected (39). Strikingly, in mice injected with recombinant
mFH or hFH, capillary wall staining is markedly reduced. This is
despite plasma FH and C3, in mice receiving recombinant FH,
having reverted to vehicle-only control levels (see above).Frontiers in Immunology | www.frontiersin.org 10Figure 8B shows glomerular C3d(g) immunostaining at day 11
(this antibody does not recognise C3, iC3b, C3c or C3b). C3d(g)
is the product of C3b cleavage by FI and cofactors including FH.
Vehicle-only control CFH-/- mice showed evidence of glomerular
reactivity with anti-C3d(g) antibody, but reduced staining is
evident in mice dosed with recombinant mFH and hFH, in
agreement with a previous ten-day study (29) with native hFH in
which C3d(g) staining decreased at day five and continued to
decline until day 11. Figure 8C summarises the results of
glomerular IgG immunostaining at day 11. In the previous
native-hFH study (29), strong glomerular FH staining was seen
at day 11 in a pattern equivalent to that seen for C3 fragments.
Therefore, any IgG detected in the current study likely represents
mouse IgG : FH immune complex deposition. No IgG staining is
observed in vehicle-only mice, but florid IgG staining occurs in
mice that received recombinant hFH. One mouse dosed with
recombinant mFH (Figure 8C) presented a less florid picture.
Overall, the appearance of anti-FH antibodies in these kidney
sections is consistent with the presence of anti-FH antibodies
detected in plasma at levels that vary between individual animals
but are higher in mice receiving recombinant FH.DISCUSSION
We used PDI co-expression to boost FH production in yeast up
to 100-fold. This could enable trials of therapeutic recombinant
FH that, to date, have been hindered by a protein shortage.
Inhibition of fluid-phase C3 consumption, suppression on self-A
B
FIGURE 5 | Glomerular C3 immunostaining in CFH-/- mice after mFH injection. (A) Representative images of C3 staining 24 hours after injection of FH (or vehicle) as
indicated below each image. White arrow indicates tubulo-interstitial C3 staining in animals receiving mouse serum-derived FH. (B) Quantitation of fluorescence
intensities expressed in arbitrary fluorescent units with horizontal bars denoting mean values. Rec. mFH, recombinant mFH.May 2021 | Volume 12 | Article 681098
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C3d(g) production are canonical functions of FH (32, 66). FH
also sequesters by-products of lipid oxidation, is a ligand for
CD11b and recognizes and promotes non-inflammatory
clearance of injured cells (37). Which of its functions is
impaired by a given disease-linked CFH mutation is often
unclear. Consequently, therapeutic administration of full-length
FH, lacking at-risk SNPs and hence possessing a full quota of
functional sites, is worth exploring for selected, genotyped
patients. Since the recipients would be heterozygous for CFH,
there would probably be two allotypic variants of FH, as well as a
set of FH-related proteins, in their circulation. Hence it seemsFrontiers in Immunology | www.frontiersin.org 11unlikely there would be any previously unencountered epitopes
present on the supplemental FH (provided it was appropriately
glycosylated). Moreover, administration of full-length
glycoprotein avoids concerns re the use of smaller versions of
FH containing just some of its 20 domains (67–70). Moreover,
FH could be more therapeutically effective than antibodies
against soluble complement proteins, which generally lack
specificity for self-surfaces.
We chose P. pastoris (71) because it grows in simple media
and has been used to produce numerous recombinant proteins.
Its use avoids oncogenic or viral nucleic acid as may occur when
mammalian cells are utilised, and toxic cell-wall pyrogens such asA B
C D
E F
FIGURE 6 | Plasma complement profile following daily FH doses. Recombinant versions of (A, C, E) murine FH, or (B, D, F) human FH were administered IP daily
to CFH-/- mice for ten days. Plots show FH (A, B), C3 (C, D) and anti-FH antibody (E, F) levels in plasma, pre-injection (P), and at 24 hours, five days, and 11 days
after the first injection. The dotted line (at 165 µg/mL) is mean plasma C3 concentration in wild-type mice, *P=0.0192, **P=0.0255, ***P=0.0033 versus pre-injection
values, Dunn’s Multiple Comparisons. Horizontal bars denote mean values.May 2021 | Volume 12 | Article 681098
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for mFH under the AOX1 promoter (72) in P. pastoris KM71H
with a S. cerevisiae a-mating factor pre-pro peptide signal leader.
This approach succeeded previously for hFH (52) although yields
were below expected. In current work, the barely detectable
amounts of mFH produced by P. pastoris in initial trials - not
increased by selecting for strains with higher gene-copy
numbers - suggested a production bottleneck. We noted
reports of using P. pastoris to make disulfide-containing
extracellular proteins, although none contain as many
disulfides and domains (40 and 20 respectively) as FH.
Nascent polypeptides destined for secretion translocate to the
ER where redox potential favours disulfides. Within the ER, PDI
(73, 74) accelerates exchange between oxidized and reduced
cysteine allowing the folding process to more quickly find the
lowest-energy disulfide pattern normally coincident with
the native one. Correctly folded proteins are transferred to the
Golgi prior to secretion, but insufficiency of PDI could allow
persistence within the ER of “mis-folded” conformations with
non-native disulfides. These trigger quality-control pathways of
the unfolded protein response (UPR) including elevatedFrontiers in Immunology | www.frontiersin.org 12chaperonin production, translation arrest and ER-associated
protein degradation (75, 76). Since the need to form 40
disulfides in overproduced FH could overwhelm the native
capacity of yeast ER to promote correct disulfide formation, we
chose to overproduce PDI alongside FH. So that PDI and FH
production coincide we used the same AOX1 promoter for both.
The codon-modified PDI gene avoided extensive sequence
identity between insert and chromosome. We incorporated
PDI and CFH genes into the yeast genome sequentially. This
created a versatile PDI+ strain that could be transformed with
heterologous genes other than CFH. The use here of separate
plasmids with different selectable markers allowed various copy
numbers to independently arise in different clones. Thus, we
could produce and test multiple clones and identify empirically
best producers.
Several reports describe co-production of proteins with
chaperonins to increase yields (77–87), but our production
gains were unprecedented. In no reported case was the target
protein a multiple-domain disulfide-rich protein. Even one
misfolded domain out of the 20 in FH could trigger the UPR.
It follows that the chances of a many-domain protein passingA
B
FIGURE 7 | Anti-FH antibodies induced by dosing with recombinant FH. (A) A test of whether injections of native [plasma-derived) mFH or rmFH or vehicle (V)] into
wild-type mice induce antibodies recognising native mFH (N-mFH), or recombinant mFH (R-mFH). Positive control: 1/250,000 dilution of mouse monoclonal antibody
to mFH. (B) Emergence of anti-FH antibodies over time after dosing in three two-month-old CFH-/- mice (displaying mild or little clinical phenotype at this point).
OD450 nm in (A, B) are read-outs of tetramethylbenzidine exposed to bound HRP-conjugated sheep anti-mouse IgG antibody (Jackson ImmunoResearch); the means
of triplicates are shown.May 2021 | Volume 12 | Article 681098
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slightly higher likelihood of achieving its native disulfide-
bonding pattern. Thus, the more disulfide-containing domains
in a protein, the greater the productivity gains to expect from
PDI overproduction. Encouragingly, this implies other multiple-
domain disulfide-rich proteins - even those that are not
produced in detectable quantities by a standard P. pastoris
strain - could be produced using our approach.
Tested in vitro, recombinant P. pastoris mFH bound mC3b,
and decayed mC3bBb, as effectively as native mFH despite a lack
of N-glycans and the presence of clipped material in our sample,
not easily removed. Following IP injection of our recombinant
mFH into CFH-/- mice, plasma FH levels were elevated at six
hours but dropped back by 24 hours. Conversely, as expected
(45), FH remained elevated in plasma of CFH-/- mice 24 hours
post-injection of native (mouse serum-derived) FH and then
declined slowly. Rapid clearance of recombinant FH was
previously observed for full-length hFH produced in moss with
partially humanized N-glycans (51). A short half-life was
likewise observed for CHO cell-produced “mini” hFH (missing
modules 6-17) (69). Both were virtually undetectable after sixFrontiers in Immunology | www.frontiersin.org 13hours. Full-length FH is too large for glomerular filtration so
given the dearth at this time point of anti-FH antibodies and a
lack of receptors for single GlcNAc residues, recombinant FH is
likely sequestered within extracellular matrix (ECM) including
that of the GBM. It was previously shown that CHO cell-
produced fluorescently tagged recombinant mFH was detected
in GBM shortly after injection into CFH-/- mice (41). Native hFH
carries disialylated N-glycans (88) and also has polyanion-
binding sites in domains 7 and 20 (62). A lack of negatively
charged N-glycans on our recombinant FH is one explanation
for an increased avidity for ECM and hence more rapid loss from
plasma. This could simply be an electrostatic effect. Another
theory, predicated on the postulated existence of intramolecular
contacts between FH-borne sialic acids and sialic acid-binding
sites on FH, proposes that when interacting with recombinant
FH, GBM sialic acids would not have to compete with sialic acids
covalently attached to FH (62).
Elevated recombinant mFH in plasma was unsustainable even
with ten daily injections. A similar observation was made (29)
following multiple daily injections of native hFH. By day five,
levels of our recombinant FH were 50% of WT, insufficient toA
B
C
FIGURE 8 | Glomerular C3 immunostaining in CFH-/- mice following repeat dosing of FH. Animals received ten daily injections of recombinant mFH or recombinant
hFH (or vehicle) and were culled at day 11. Glomerular C3 (A), C3d (B) and IgG (C) were assessed, and representative images shown. Quantitation of fluorescence
intensity, in arbitrary fluorescent units, is plotted with horizontal bars denoting mean values. *P=0.0317, **P=0.0159 versus PBS, Mann-Whitney Test.May 2021 | Volume 12 | Article 681098
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(and C3) levels between five and eleven days is likely connected
to emergence of anti-FH antibodies. CFH-/- mice should have
some immune tolerance to mFH due to their mFH-related
proteins (mFHR) A, B and C (89), and despite the FH
knockout altering immune tolerance (90). Indeed, Figure 6
shows that a substantial antibody titre arose between days 5
and 11 only in the case of recombinant FH. Anti-FH antibodies
induced in WT mice by recombinant mFH, recognized
recombinant FH selectively (Figure 7A), suggesting that
epitopes might include GlcNAc residues or the “frayed ends”
of the clipped backbone. A separate 41-day experiment (with FH
injected at days 0 and 24) confirmed recombinant mFH is more
immunogenic than native mFH in CFH-/- mice (Figure 7B).
Administration of recombinant versions of mFH and hFH
temporarily raised plasma levels of intact C3 (Figure 6). Dose for
dose, however, they resulted in smaller and shorter-lived
elevations of intact C3 than did native mFH. No C3-staining in
mesangial or interstitial tubular regions was detected in
recombinant mFH-treated mice consistent with sub-wild-type
levels of C3 in plasma. These observations may be explained as
secondary consequences of the more rapid clearance of
recombinant FH, given that plasma levels of intact C3 mirrored
those of FH.
In previous multiple daily-dose experiments, using native
hFH, glomerular staining with polyclonal anti-C3 antibody
declined after five days but reappeared after ten (29). This
breakdown in the propensity of daily hFH injections to control
C3 fragment deposition between five and ten days was linked to
the appearance of anti-hFH antibodies. In the current study,
treatment with recombinant mFH likewise significantly reduced
glomerular anti-C3 staining (Figure 6). But, unlike in the
previous study, this reduction persisted beyond the tenth daily
injection of recombinant mFH, despite low FH and C3 levels
in plasma.
Plasma levels of FH do not necessarily reflect how much FH
is present in the GBM where FH can bind many partners
including GAGs, sialic acids (see above) and, if present, C3
fragments. Thus, recombinant FH could have a long residency
time. When FH is continuously supplied by regular IP injections,
and notwithstanding an increasing titre of circulating anti-FH
antibodies, a steady-state quantity of functional FH could be
established in the GBM that is adequate for preventing
both further local generation and deposition of nascent C3b
and proteolytic processing of existing C3b. Indeed, in both
previous and current studies, staining for C3d(g) was also
reduced, compared to controls, after ten days of recombinant
mFH treatment.
A serendipitous scenario, in which circulating recombinant
FH and C3 levels are low while recombinant FH residency in the
GBM is high, could be optimal from the narrow perspective of
resolving C3 fragment deposition in glomeruli. It is reminiscent
of the CFH-/-/Crry-/- double-knockout mouse in which a mild
phenotype (compared to CFH-/-) was attributed to plasma C3
depletion. It is the inverse of the scenario underlying the severe
phenotype associated with homozygosity for the mFH mutantFrontiers in Immunology | www.frontiersin.org 14W1206R (42). In these animals fluid-phase AP regulation and
hence C3 levels are maintained but C3b amplification on surfaces
is unregulated because W1183R has low affinity for surfaces. The
benefit observed in our study might be temporary as, longer
term, higher titres develop of anti-FH antibodies or antibodies
arising to the GBM-bound form of FH, and antibody-antigen
complexes could accumulate in the kidney. It is highly unlikely
that human FH produced in this strain would be suitable for
human therapy. However, the boost in yield obtained by co-
expression with PDI suggest that migration of this strategy to a
glycoengineered strain of P. pastoris (91) capable of decorating
proteins with complex, mammalian-like N-glycans would be
worth investigating.
In conclusion we have developed a platform for production of
large quantities of the large and important category of proteins
that are rich in disulfide bonds and possess many domains. These
are currently heavily under-represented in the list of
recombinant proteins. Our recombinant versions of FH are
biologically active in vitro and in vivo. An obvious way to
reduce the immunogenicity of our products would be to
circumvent “clipping” and to use a strain of P. pastoris that
decorates glycoproteins with the desired N-glycans to yield FH
with a native conformation and immune tolerance.
Serendipitously we show that a good, but not necessarily
clinically desirable, means of resolving C3 fragment deposition
in glomeruli is to leave C3 consumption in fluid phase largely
unchecked while targeting regulation to the GBM.DATA AVAILABILITY STATEMENT
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